Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 200Breast Neoplasms 124Carcinoma, Non-Small-Cell Lung 121Glioblastoma 93Neoplasms 75Ovarian Neoplasms 72Rectal Neoplasms 61Brain Neoplasms 59Lung Neoplasms 56Colonic Neoplasms 55Neoplasm Metastasis 51Glioma 49Carcinoma, Renal Cell 46Fallopian Tube Neoplasms 38Gliosarcoma 35Pancreatic Neoplasms 31Carcinoma, Hepatocellular 28Melanoma 26Adenocarcinoma of Lung 24Astrocytoma 21Stomach Neoplasms 20Uterine Cervical Neoplasms 16Recurrence 16Prostatic Neoplasms 16Liver Neoplasms 16Adenocarcinoma, Bronchiolo-Alveolar 16Esophageal Neoplasms 15Adenocarcinoma 15Carcinoma, Ovarian Epithelial 14Kidney Neoplasms 13

Interventions

Gemcitabine 5130-nm albumin-bound paclitaxel 5Albumin-Bound Paclitaxel 4napabucasin 3Ocoxin 3Irinotecan 3Fluorouracil 3Paclitaxel 2Oxaliplatin 2Nivolumab 2Leucovorin 2Cyclophosphamide 2Capecitabine 2Bevacizumab 2trifluridine tipiracil drug combination 1trametinib 1pralsetinib 1pembrolizumab 1ozanimod 1halofantrine 1guadecitabine 1ficlatuzumab 1Ursodeoxycholic Acid 1Sorafenib 1Radiotherapy 1Pemetrexed 1Oviposition 1Nadroparin 1Lenalidomide 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Digestive System Diseases × Bevacizumab × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡